Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

Li Wei, Yu Kai Su, Chien Min Lin, Tsu Yi Chao, Shang Pen Huang, Thanh Tuan Huynh, Hsun Jin Jan, Jacqueline Whang-Peng, Jeng Fong Chiou, Alexander T H Wu, Michael Hsiao

研究成果: 雜誌貢獻文章

13 引文 (Scopus)

摘要

Standard interventions for glioma include surgery, radiation and chemotherapies but the prognosis for malignant cases such as glioblastoma multiforme remain grim. Even with targeted therapeutic agent, bevacitumab, malignant glioma often develops resistance and recurrence. Thus, developing alternative interventions (therapeutic targets, biomarkers) is urgently required. Bruton's tyrosine kinase (Btk) has been long implicated in B cell malignancies but surprisingly it has recently been shown to also play a tumorigenic role in solid tumors such as ovarian and prostate cancer. Bioinformatics data indicates that Btk is significantly higher in clinical glioma samples as compared to normal brain cells and Btk expression level is associated with stage progression. This prompts us to investigate the potential role of Btk as a therapeutic target for glioma. Here, we demonstrate Btk expression is associated with GBM tumorigenesis. Down-regulation of Btk in GBM cell lines showed a significantly reduced abilities in colony formation, migration and GBM sphere-forming potential. Mechanistically, Btk-silenced cells showed a concomitant reduction in the expression of CD133 and Akt/mTOR signaling. In parallel, Ibrutinib (a Btk inhibitor) treatment led to a similar anti-tumorigenic response. Using xenograft mouse model, tumorigenesis was significantly reduced in Btk-silenced or ibrutinib-treated mice as compared to control counterparts. Finally, our glioma tissue microarray analysis indicated a higher Btk staining in the malignant tumors than less malignant and normal brain tissues. Collectively, Btk may represent a novel therapeutic target for glioma and ibrunitib may be used as an adjuvant treatment for malignant GBM.
原文英語
頁(從 - 到)69961-69975
頁數15
期刊Oncotarget
7
發行號43
DOIs
出版狀態已發佈 - 2016

指紋

Glioma
Carcinogenesis
Stem Cells
Phenotype
Agammaglobulinaemia tyrosine kinase
PCI 32765
Tissue Array Analysis
Therapeutics
Neoplasms
Brain
Glioblastoma
Computational Biology
Heterografts
Ovarian Neoplasms
Prostatic Neoplasms
B-Lymphocytes
Down-Regulation
Biomarkers
Radiation
Staining and Labeling

ASJC Scopus subject areas

  • Oncology

引用此文

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. / Wei, Li; Su, Yu Kai; Lin, Chien Min; Chao, Tsu Yi; Huang, Shang Pen; Huynh, Thanh Tuan; Jan, Hsun Jin; Whang-Peng, Jacqueline; Chiou, Jeng Fong; Wu, Alexander T H; Hsiao, Michael.

於: Oncotarget, 卷 7, 編號 43, 2016, p. 69961-69975.

研究成果: 雜誌貢獻文章

@article{fca0c60606904092a01fee800be84bb3,
title = "Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes",
abstract = "Standard interventions for glioma include surgery, radiation and chemotherapies but the prognosis for malignant cases such as glioblastoma multiforme remain grim. Even with targeted therapeutic agent, bevacitumab, malignant glioma often develops resistance and recurrence. Thus, developing alternative interventions (therapeutic targets, biomarkers) is urgently required. Bruton's tyrosine kinase (Btk) has been long implicated in B cell malignancies but surprisingly it has recently been shown to also play a tumorigenic role in solid tumors such as ovarian and prostate cancer. Bioinformatics data indicates that Btk is significantly higher in clinical glioma samples as compared to normal brain cells and Btk expression level is associated with stage progression. This prompts us to investigate the potential role of Btk as a therapeutic target for glioma. Here, we demonstrate Btk expression is associated with GBM tumorigenesis. Down-regulation of Btk in GBM cell lines showed a significantly reduced abilities in colony formation, migration and GBM sphere-forming potential. Mechanistically, Btk-silenced cells showed a concomitant reduction in the expression of CD133 and Akt/mTOR signaling. In parallel, Ibrutinib (a Btk inhibitor) treatment led to a similar anti-tumorigenic response. Using xenograft mouse model, tumorigenesis was significantly reduced in Btk-silenced or ibrutinib-treated mice as compared to control counterparts. Finally, our glioma tissue microarray analysis indicated a higher Btk staining in the malignant tumors than less malignant and normal brain tissues. Collectively, Btk may represent a novel therapeutic target for glioma and ibrunitib may be used as an adjuvant treatment for malignant GBM.",
keywords = "Bruton's tyrosine kinase, Cancer stem cells, Glioma, Ibrutinib",
author = "Li Wei and Su, {Yu Kai} and Lin, {Chien Min} and Chao, {Tsu Yi} and Huang, {Shang Pen} and Huynh, {Thanh Tuan} and Jan, {Hsun Jin} and Jacqueline Whang-Peng and Chiou, {Jeng Fong} and Wu, {Alexander T H} and Michael Hsiao",
year = "2016",
doi = "10.18632/oncotarget.11572",
language = "English",
volume = "7",
pages = "69961--69975",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "43",

}

TY - JOUR

T1 - Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

AU - Wei, Li

AU - Su, Yu Kai

AU - Lin, Chien Min

AU - Chao, Tsu Yi

AU - Huang, Shang Pen

AU - Huynh, Thanh Tuan

AU - Jan, Hsun Jin

AU - Whang-Peng, Jacqueline

AU - Chiou, Jeng Fong

AU - Wu, Alexander T H

AU - Hsiao, Michael

PY - 2016

Y1 - 2016

N2 - Standard interventions for glioma include surgery, radiation and chemotherapies but the prognosis for malignant cases such as glioblastoma multiforme remain grim. Even with targeted therapeutic agent, bevacitumab, malignant glioma often develops resistance and recurrence. Thus, developing alternative interventions (therapeutic targets, biomarkers) is urgently required. Bruton's tyrosine kinase (Btk) has been long implicated in B cell malignancies but surprisingly it has recently been shown to also play a tumorigenic role in solid tumors such as ovarian and prostate cancer. Bioinformatics data indicates that Btk is significantly higher in clinical glioma samples as compared to normal brain cells and Btk expression level is associated with stage progression. This prompts us to investigate the potential role of Btk as a therapeutic target for glioma. Here, we demonstrate Btk expression is associated with GBM tumorigenesis. Down-regulation of Btk in GBM cell lines showed a significantly reduced abilities in colony formation, migration and GBM sphere-forming potential. Mechanistically, Btk-silenced cells showed a concomitant reduction in the expression of CD133 and Akt/mTOR signaling. In parallel, Ibrutinib (a Btk inhibitor) treatment led to a similar anti-tumorigenic response. Using xenograft mouse model, tumorigenesis was significantly reduced in Btk-silenced or ibrutinib-treated mice as compared to control counterparts. Finally, our glioma tissue microarray analysis indicated a higher Btk staining in the malignant tumors than less malignant and normal brain tissues. Collectively, Btk may represent a novel therapeutic target for glioma and ibrunitib may be used as an adjuvant treatment for malignant GBM.

AB - Standard interventions for glioma include surgery, radiation and chemotherapies but the prognosis for malignant cases such as glioblastoma multiforme remain grim. Even with targeted therapeutic agent, bevacitumab, malignant glioma often develops resistance and recurrence. Thus, developing alternative interventions (therapeutic targets, biomarkers) is urgently required. Bruton's tyrosine kinase (Btk) has been long implicated in B cell malignancies but surprisingly it has recently been shown to also play a tumorigenic role in solid tumors such as ovarian and prostate cancer. Bioinformatics data indicates that Btk is significantly higher in clinical glioma samples as compared to normal brain cells and Btk expression level is associated with stage progression. This prompts us to investigate the potential role of Btk as a therapeutic target for glioma. Here, we demonstrate Btk expression is associated with GBM tumorigenesis. Down-regulation of Btk in GBM cell lines showed a significantly reduced abilities in colony formation, migration and GBM sphere-forming potential. Mechanistically, Btk-silenced cells showed a concomitant reduction in the expression of CD133 and Akt/mTOR signaling. In parallel, Ibrutinib (a Btk inhibitor) treatment led to a similar anti-tumorigenic response. Using xenograft mouse model, tumorigenesis was significantly reduced in Btk-silenced or ibrutinib-treated mice as compared to control counterparts. Finally, our glioma tissue microarray analysis indicated a higher Btk staining in the malignant tumors than less malignant and normal brain tissues. Collectively, Btk may represent a novel therapeutic target for glioma and ibrunitib may be used as an adjuvant treatment for malignant GBM.

KW - Bruton's tyrosine kinase

KW - Cancer stem cells

KW - Glioma

KW - Ibrutinib

UR - http://www.scopus.com/inward/record.url?scp=84994236108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994236108&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11572

DO - 10.18632/oncotarget.11572

M3 - Article

C2 - 27564106

AN - SCOPUS:84994236108

VL - 7

SP - 69961

EP - 69975

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -